News & Updates

Original New Drug Application Approvals by US FDA (01-15 September 2023)

15 Sep 2023

New drug applications approved by US FDA as of 01-15 September 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01-15 September 2023)

15 Sep 2023

Postnatal SSRI treatment helps with postnatal depression–associated problems

06 Sep 2023

Treating postnatal depression with selective serotonin reuptake inhibitors (SSRIs) may be beneficial for both mothers and their children in the long term, with a recent study showing that SSRIs can reduce the risk of several negative outcomes, such as maternal depression and child behavioural problems, according to a study.

Postnatal SSRI treatment helps with postnatal depression–associated problems

06 Sep 2023

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

05 Sep 2023

Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

05 Sep 2023

Infertility treatment carries increased risk of stroke hospitalization

04 Sep 2023

Women who conceive following infertility treatment appear to have a higher likelihood of stroke-related hospitalization within 12 months of delivery as compared with those who spontaneously conceive, according to a study.

Infertility treatment carries increased risk of stroke hospitalization

04 Sep 2023

Music therapy aids perimenopausal women

04 Sep 2023

Music therapy appears to benefit perimenopausal women by easing their psychological and emotional symptoms, according to a study.

Music therapy aids perimenopausal women

04 Sep 2023

US FDA greenlights first pill for postpartum depression

31 Aug 2023 by

The US Food and Drug Administration (FDA) has approved the first oral medication for postpartum depression in adults, giving clinicians a new therapeutic option for this debilitating condition.

US FDA greenlights first pill for postpartum depression

31 Aug 2023

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

31 Aug 2023 by

A retrospective cohort study of twin pregnancies in Hong Kong has identified general anaesthesia (GA) and use of oxytocin as significant risk factors for all postpartum haemorrhage (PPH; ≥500 mL). The study also shows that GA, in vitro fertilization (IVF), antepartum haemorrhage, placental abruption, and placenta praevia (PP) are significantly associated with major PPH (>1,000 mL), while IVF, PP, and obesity are significant risk factors for severe PPH (>1,500 mL).

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

31 Aug 2023

Niraparib maintenance prolongs PFS in advanced ovarian cancer

29 Aug 2023 by

Maintenance therapy with niraparib significantly extends progression-free survival (PFS) compared with placebo in patients with newly diagnosed advanced ovarian cancer who responded to treatment with first-line platinum-based chemotherapy, according to the PRIME* trial.

Niraparib maintenance prolongs PFS in advanced ovarian cancer

29 Aug 2023

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

19 Aug 2023

For pregnant women at risk of delivering preterm, intravenous administration of magnesium sulfate prior to preterm birth at 30–34 week of gestation does not appear to minimize the chances of child survival free of cerebral palsy at 2 years, as shown in a study.

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

19 Aug 2023

OGTT-based model predicts GDM in pregnant women

18 Aug 2023

The current diagnostic criteria being used to predict gestational diabetes mellitus (GDM) is not fully reliable, but adding oral glucose tolerance test (OGTT) to the model may improve early prediction of GDM, according to a study.

OGTT-based model predicts GDM in pregnant women

18 Aug 2023

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (01-15 September 2023)

Original New Drug Application Approvals by US FDA (01-15 September 2023)

Postnatal SSRI treatment helps with postnatal depression–associated problems

Postnatal SSRI treatment helps with postnatal depression–associated problems

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?

Infertility treatment carries increased risk of stroke hospitalization

Infertility treatment carries increased risk of stroke hospitalization

Music therapy aids perimenopausal women

Music therapy aids perimenopausal women

US FDA greenlights first pill for postpartum depression

US FDA greenlights first pill for postpartum depression

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

General anaesthesia and oxytocin significantly associated with PPH in twin pregnancies

Niraparib maintenance prolongs PFS in advanced ovarian cancer

Niraparib maintenance prolongs PFS in advanced ovarian cancer

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

Magnesium sulfate for women at risk of preterm birth does not reduce cerebral palsy risk

OGTT-based model predicts GDM in pregnant women

OGTT-based model predicts GDM in pregnant women